Acute Kidney Injury Emerges as a Meaningful Toxicity After CD19 CAR T Therapy
CD19 CAR T-cell therapy has changed the treatment course for relapsed or refractory non-Hodgkin lymphoma by producing durable remissions in a population with few effective options. The renal safety profile of this therapy has not received the same attention as cytokine release syndrome or immune effector cell-associated neurologic syndrome, yet kidney injury can reshape the entire course of care at the bedside. In a study published in Haematologica, acute kidney injury appeared with enough frequency and enough prognostic weight to warrant closer monitoring from the moment infusion begins.
A preliminary review of the Food and Drug Administration adverse event reporting system identified a disproportionately high rate of renal adverse events among nearly 6,000 CAR T adverse event reports. That signal pushed the question from theoretical concern to practical risk assessment. The subsequent single-center analysis of 399 patients with non-Hodgkin lymphoma treated with CD19 CAR T cells showed acute kidney injury in 10% of patients at any grade and in 5% at grade 2 or higher. Pre-renal injury dominated the clinical picture, accounting for 72% of cases. In other words, many of these events were not mysterious intrinsic kidney failures; they were the expected renal consequence of hemodynamic stress, inflammatory illness, and the physiologic strain that often accompanies CAR T toxicity.
One sentence captures the clinical urgency plainly: kidney injury was common enough to matter, and it was not benign when it appeared.
Inflammation, Capillary Leak, and Renal Hypoperfusion
The biology fits the clinical pattern. Patients who developed cytokine release syndrome or neurotoxicity were more likely to experience acute kidney injury, linking renal dysfunction to the same systemic inflammatory cascade that drives other recognized CAR T complications. High inflammatory cytokines, including IL-6 and TNF-α, were also associated with kidney injury, as was low serum albumin. Those factors point toward a milieu of vascular leak, third spacing, reduced effective circulating volume, and compromised renal perfusion rather than isolated nephrotoxic damage alone.
This matters because the kidney often serves as a sentinel organ during systemic inflammatory injury. When plasma proteins fall and cytokine signaling rises, intravascular volume can become functionally depleted even when total body fluid is not low. Renal blood flow falls, creatinine rises, and a patient who began treatment with preserved function can rapidly cross into a clinically important stage of kidney injury. The predominance of pre-renal causes in this cohort supports that pathway and suggests that early fluid assessment, blood pressure surveillance, and prompt treatment of cytokine release syndrome may protect renal function.
The study does not suggest that kidney injury is merely an epiphenomenon of severe illness. It signals a measurable toxicity with a biologic backbone that can be tracked using routine laboratory markers already available in most treatment centers.
Baseline Kidney Function Did Not Predict the Outcomes That Followed
Pre-CAR T renal dysfunction was not associated with worse outcomes in this cohort, which is an important distinction for clinicians deciding whether an elevated creatinine before therapy should automatically alter treatment plans. Baseline kidney impairment did not carry the same prognostic meaning as kidney injury that developed after infusion. The timing of the insult appears to matter more than the presence of pre-existing dysfunction alone.
Post-treatment kidney injury, by contrast, carried real consequences. Patients who developed acute kidney injury after CAR T therapy had lower overall survival than those who did not. The abstract does not provide the mechanistic explanation for that survival difference, but the association is clinically plausible. Kidney injury may mark patients who endured a more intense inflammatory syndrome, more severe hemodynamic instability, greater organ stress, or a less resilient physiologic reserve during the critical post-infusion period. In a therapy already defined by a narrow window between efficacy and toxicity, renal injury may function as both complication and severity marker.
A second sentence deserves equal emphasis: three patients required hemodialysis.
Chronic Kidney Disease Was Uncommon, but Severe Renal Failure Still Occurred
Despite the acute burden, evolution to chronic kidney disease was rare. That finding offers some reassurance about long-term renal trajectory in most patients who survive the immediate treatment period. Still, “rare” does not mean clinically trivial. Hemodialysis in three patients represents severe renal failure in a therapy population that often enters treatment with advanced malignancy, prior chemotherapy exposure, and limited physiologic reserve.
The study therefore draws a boundary between transient renal stress and serious kidney injury. Most episodes were pre-renal and presumably reversible with supportive care, but the presence of dialysis-requiring cases shows that the spectrum extends beyond mild creatinine fluctuations. For transplant and cellular therapy teams, this means kidney monitoring cannot be treated as a secondary task. Renal function should be followed in parallel with hemodynamics, cytokine release syndrome grading, and neurologic assessment, particularly in the early days after infusion when inflammatory toxicity peaks.
Biomarkers May Help Identify Patients at Highest Risk
The association between low albumin, elevated IL-6, elevated TNF-α, and acute kidney injury points toward a biomarker strategy that could be built into routine CAR T surveillance. Those markers are not exotic research-only measurements in many centers; they are familiar signals of inflammatory burden and physiologic stress. If validated prospectively, they could help identify the patients most likely to develop renal dysfunction before creatinine rises.
Such a strategy would be valuable for several reasons. It could guide more intensive monitoring, more aggressive volume assessment, earlier recognition of cytokine release syndrome, and faster intervention when hypotension or third spacing develops. It may also help clinicians distinguish a patient with modest baseline renal impairment who is likely to tolerate therapy from a patient whose inflammatory profile suggests higher risk for post-infusion kidney injury. The study does not establish a biomarker-based protocol, but it lays the groundwork for one.
For now, the message is direct: acute kidney injury is a common CAR T complication, it clusters with systemic inflammatory toxicity, and it carries prognostic weight. In a field that has rightly focused on neurologic and cytokine-mediated adverse events, the kidney deserves a place in the core toxicity conversation.